MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Novartis AG

Closed

110.8 1.17

Overview

Share price change

24h

Current

Min

109.17

Max

110.8

Key metrics

By Trading Economics

Income

-369M

2.8B

Sales

386M

14B

P/E

Sector Avg

18.992

63.778

EPS

1.98

Dividend yield

3.47

Profit margin

20.8

Employees

75,883

EBITDA

-426M

5.2B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+0.21% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.47%

2.39%

Market Stats

By TradingEconomics

Market Cap

6.9B

221B

Previous open

109.63

Previous close

110.8

Technical Score

By Trading Central

Confidence

Bearish Evidence

Novartis AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lut 2025, 06:57 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

31 sty 2025, 09:49 UTC

Earnings

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

31 sty 2025, 08:06 UTC

Earnings

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

31 sty 2025, 06:32 UTC

Earnings

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

17 mar 2025, 07:34 UTC

Market Talk

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

4 mar 2025, 18:45 UTC

Earnings

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

11 lut 2025, 09:25 UTC

Top News
Acquisitions, Mergers, Takeovers

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

11 lut 2025, 06:42 UTC

Top News
Acquisitions, Mergers, Takeovers

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

11 lut 2025, 06:22 UTC

Acquisitions, Mergers, Takeovers

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

11 lut 2025, 06:20 UTC

Acquisitions, Mergers, Takeovers

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

11 lut 2025, 06:19 UTC

Acquisitions, Mergers, Takeovers

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

11 lut 2025, 06:18 UTC

Acquisitions, Mergers, Takeovers

Novartis: Deal Is Expected to Close in 1H of 2025

11 lut 2025, 06:18 UTC

Acquisitions, Mergers, Takeovers

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

11 lut 2025, 06:17 UTC

Acquisitions, Mergers, Takeovers

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

11 lut 2025, 06:16 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Anthos Therapeutics for $925M Upfront

11 lut 2025, 06:15 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Anthos Therapeutics

4 lut 2025, 15:16 UTC

Top News

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

4 lut 2025, 08:12 UTC

Market Talk
Earnings

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

31 sty 2025, 13:56 UTC

Earnings

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

31 sty 2025, 09:59 UTC

Hot Stocks

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

31 sty 2025, 07:50 UTC

Market Talk

Novartis's Outlook Exceeds Market Views -- Market Talk

31 sty 2025, 07:46 UTC

Market Talk
Earnings

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

31 sty 2025, 06:03 UTC

Earnings

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

31 sty 2025, 06:02 UTC

Earnings

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

31 sty 2025, 06:02 UTC

Earnings

Novartis Issues 2025 View

31 sty 2025, 06:02 UTC

Earnings

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

31 sty 2025, 06:02 UTC

Earnings

Novartis 4Q Oper Pft $3.53B

31 sty 2025, 06:02 UTC

Earnings

Novartis 4Q Net Pft $2.82B

31 sty 2025, 06:02 UTC

Earnings

Analysts Saw Novartis 4Q Core Operating Profit at $4.44B

31 sty 2025, 06:02 UTC

Earnings

Novartis 4Q Core Operating Profit $4.86B

Peer Comparison

Price change

Novartis AG Forecast

Price Target

By TipRanks

0.21% upside

12 Months Forecast

Average 111 USD  0.21%

High 125 USD

Low 97 USD

Based on 2 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

0

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

109.97 / 112.06Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.